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Introduction
Before testing new drugs, theranostics or medical devices 
containing one or more new bioactive biomaterials in “First-
in-Man Phase 1 Clinical Trials”, highly valid and reliable data 
are required. Lack of transferability of experimental data of in 
vivo animal trials and their inequivalency to human biology 
necessitate the use of human cell-derived model systems 
that can range from single cells via three-dimensional (3D) 
models to organs-on-chips.1–6 Taking this into consideration, 
human-tissue-related 3D cell cultures have the ability to reca-
pitulate characteristics of tissue physiology and pathophysiol-
ogy and are emerging as an attractive model system to provide 
more reliable preclinical outcomes.
Autologous skin or tissue-engineered skin grafts have 
been used as epidermal/dermal substitutes to treat burns and 
wounds.7–10 Commercially available dermal constructs for 
clinical use include either chemically treated allografts 
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Three-dimensional cell culture systems are urgently needed for cytocompatibility testing of biomaterials. This work 
aimed at the development of three-dimensional in vitro dermal skin models and their optimization for cytocompatibility 
evaluation. Initially “murine in vitro dermal construct” based on L929 cells was generated, leading to the development 
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matrix revealing filopodia-like morphology and a uniform distribution of normal human dermal fibroblasts in matrix. 
CellTiter-Glo was found to be the optimal cell viability assay among those analyzed. CellTiter-Blue reagent affected 
the cell morphology of normal human dermal fibroblasts (unlike L929), suggesting an interference with cell biological 
activity, resulting in less reliable viability data. On the other hand, RealTime-Glo provided a linear signal only with a very 
low cell density, which made this assay unsuitable for this system. CellTiter-Glo adapted to three-dimensional dermal 
construct by optimizing the “shaking time” to enhance the reagent penetration and maximum adenosine triphosphate 
release, indicating 2.4 times higher viability value by shaking for 60 min than for 5 min. In addition, viability results showed 
that cells were viable inside the matrix. This model would be further advanced with more layers of skin to make a full 
thickness model.
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(e.g. AlloDerm®)11 or in vitro cultured human fibroblasts in 
a matrix (Dermagraft®).12,13 One recent application of grafts 
is in the field of in vitro testing systems.14,15 Skin substitutes 
have been used in pharmacological and basic research either 
for hazard assessment of chemical compounds (e.g. skin 
irritation/absorption/corrosion)14,16–19 or to understand fun-
damental processes (e.g. the effect of fibroblasts on microen-
vironment for epidermal regeneration).20,21 The development 
of in vitro tools for testing has also been stimulated by 
evolving regulations: the European Union (EU) 7th amend-
ment of the “Cosmetics Directive” imposed to replace all 
animal experiments on cutaneous resorption with reliable in 
vitro tests by the year 2009.22 This led to the development of 
the 3Rs principle “replacement, reduction and refinement.”23 
In agreement with this principle, cell lines are used to assess 
general in vitro cytotoxicity based on DIN EN ISO 10993-5, 
while any specific cytotoxicity should be tested using specific 
primary cells.24 In addition, in vitro bioevaluation is more 
accurate using 3D testing systems than two-dimensional (2D) 
cultures.25–27 Cell-based assays being routinely used for thera-
peutic screening are the methods based on a specific bio-
marker for detecting cell viability and cytotoxicity with an 
established 2D cell culture system. There have been precise 
adaptations of these assays to spheroids-based 3D sys-
tems;28–32 however, to evaluate the viability of primary cells-
based 3D model, it is crucial to select the best suited assay for 
each cell type in 2D and then in 3D system.
In this work, a human dermal skin model was developed 
and aimed at the future preclinical testing of new biomaterials 
for wound healing, reducing the number of needed animal 
experiments. Human skin is composed of three layers: epider-
mis, dermis, and the underlying hypodermis, also called sub-
cutaneous connective tissue.33 A preliminary 3D dermal 
model using L929 cells (mouse fibroblast cell line) was con-
structed and named as “murine in vitro dermal construct.” 
Knowledge arising from this model allowed the subsequent 
development of human dermal skin model using primary nor-
mal human dermal fibroblasts (NHDF), named as “human in 
vitro dermal construct.” The models were characterized for 
cell viability and morphology as a function of time. Different 
viability assays were applied on the models under different 
conditions to select the best one as advanced testing system 
for preclinical evaluation. There is a need for more than one 
type of test methods to imply in the 3D cell culture system 
based on different parameters, for example, nicotinamide 
adenine dinucleotide phosphate (NADPH) enzyme activity, 
adenosine triphosphate (ATP) content of cells, and/or DNA 
content to reveal all the different aspects of nonphysiologic or 
pathophysiologic reactions occurring in this system.
Methods
Cell source and materials
L929 cells were obtained from DSMZ (German Collec-
tion of Microorganisms and Cell Cultures). Primary cells 
including NHDF and normal human epidermal keratino-
cytes (NHEK) were obtained from PromoCell. ISO 
standardized materials, that is, polyethylene (PE) and 
zinc diethyldithiocarbamate containing polyurethane 
(ZDEC-PU) were obtained from Good fellow and Hatano 
Research Institute, respectively, and used as control 
materials for cytotoxicity testing. Collagen type I (col. I) 
from rat tail tendons was obtained from Ibidi. Lysis solu-
tion of 9% Triton® X-100 in water from Promega was 
used to create “lysis control.”
Dermal construct fabrication
Gelation of col. I solution was performed in 10X media 
(M199-Sigma), in the presence of additives (L-glutamine) 
and sodium bicarbonate (NaHCO3) resulting in a final col. 
I concentration of 1.5 mg/mL (containing a final salt con-
centration of 1X mixture with a pH of 7.2–7.4).
L929 cells maintained in cell culture media RPMI 1640 
with stable glutamine (PAN Biotech) containing 10% fetal 
bovine serum (FBS; PAN Biotech) under physiological 
culture conditions (37°C, 5% CO2), and subcultured using 
0.25% Trypsin (Gibco).
NHDF were maintained in fibroblasts growth media 
2 (FGM2, Promocell) under the physiological culture 
conditions (37°C, 5% CO2), and subcultured using 
DetachKit2-Promocell HEPES BSS (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid buffered saline solu-
tion); 0.04% trypsin/0.03% Ethylenediaminetetraacetic 
acid (EDTA); trypsin neutralizing solution (TNS) con-
taining 0.05% trypsin inhibitor from soybean/0.1% 
bovine serum albumin).
Dermal constructs were prepared by fabricating acellu-
lar (200 µL) and cellular layers (400 µL) of col. I matrix on 
polyester membrane of 12 well insert (Corning) constitut-
ing a 5-mm thick dermal construct.
Cellular layers: Actively dividing mitotic cells (8 × 105 
L929 cells/mL to obtain the murine in vitro dermal con-
struct; 8 × 104 NHDF cells/mL to obtain the human in vitro 
dermal construct) were embedded in col. I solution and 
poured onto the top of the previously deposited acellular 
col. I layer. When the cellularized matrix underwent gela-
tion, the system was fed with fresh cell culture medium. 
The system was incubated for 5–7 days to allow hydrogel 
remodeling by the embedded cells.
Morphological analysis
Morphological appearance of cells in 2D (cells grown on 
tissue culture polystyrene (TCPS)) and 3D col. I matrix 
was assessed using bright field and fluorescent microscopy 
(Olympus IX51). Fluorescent staining was performed using 
Live/Dead staining kit-Promokine containing calcein-AM 
and ethidium homodimer III (EthD-III) to see live and dead 
cells in 2D and/or 3D matrix. F-actin/nuclei staining was 
performed using Phalloidin/DAPI stain-Promokine.
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Cell viability analysis
To assess the viability of the cells in 2D and 3D system 
quantitatively, different cell viability and cytotoxicity 
assays, for example, CellTiter-Blue® (CTB), CytoTox-
ONE™ (CTO), RealTime-Glo™ MT (RTG MT), and 
CellTiter-Glo® (CTG)-Promega, were evaluated to moni-
tor cell viability of the respective cell types according to 
standard protocols and for their 3D dermal constructs with 
modified standard protocols.
The CTG assay was used for matrix-based 3D cultured 
cells for the first time after optimizing the shaking time 
using the reagent at the same concentration as described in 
the standard protocol with monolayer culture. The parallel 
Z-stack microscopic observation showed that 60 mins of 
shaking time (10 min for signal stabilization) was enough 
to lyse cells and release the maximum ATP content. The 
effect on the decay of signal over time was confirmed by 
recording the luminescence over time.
The CTB assay was used for matrix-based 3D cultured 
cells for the first time after optimizing the test design using 
the reagent at the same concentration as described in the 
standard protocol with monolayer culture. The reagent was 
added only on the top of the construct, shaken for a few 
minutes, and incubated for 2 h at 37°C. The tiny seeping 
reagent was transferred every 40 min (T40 min, T80 min, T120 min) 
back to the insert during the incubation period. Compared 
to higher incubation times, 2 h was also good enough to 
reduce blue resazurin to pink resorufin in this 3D system.
Statistical analysis
Experiments were carried out in triplicates (n = 3) and 
results were expressed as mean ± standard deviation. For 
statistical analysis, GraphPad Prism 5.00.288 (Inc., San 
Diego, CA, USA) was used to evaluate the significance of 
the differences in cell viability data. T-test was used when 
the comparison involved two groups. Significance between 
groups was considered for p < 0.05.
Results
L929 cells in 2D and 3D models: 
cytocompatibility evaluation
Morphology of cells changed depending if they had been 
cultured on 2D flat surface or within a 3D col. I matrix: a 
well-connected network of L929 cells was found in 3D 
matrix (Figure 1(b)) while in 2D cultures, cells showed flat 
morphology (Figure 1(a)).
We intended to develop an in vitro human dermal skin 
model for bioevaluation of novel drug-free antibacterial 
hybrid biopolymers for medical applications. Therefore, 
apart from the company’s recommended controls, we used 
according to the DIN EN ISO 10993-5 standardized posi-
tive (PE) and negative control materials (ZDEC-PU), since 
we intended to analyze the novel biomaterials’ interaction 
with our 3D system.
CTB assay measures cell viability and is based on the 
ability of living cells to convert a redox dye (resazurin) into 
a fluorescent end-product (resorufin), while CTO assay 
evaluates the cytotoxicity by measuring the release of lac-
tate dehydrogenase (LDH) from cells with a damaged mem-
brane. Both assays were performed in multiplexed format to 
get more information from the same sample. As a proof of 
concept, the performed experiment (Figure 2(a)) showed 
that CTB assay works well with L929 cells, indicating an 
increasing viability signal with an increase in cell number.
This was also confirmed by monitoring the cytocompat-
ibility of ISO standardized positive (PE) and negative con-
trol materials (ZDEC-PU) with L929 cells, indicating cell 
viability and cytotoxicity signals, respectively (Figure 2(b)). 
The fluorescent micrographs using Live/Dead staining of 
L929 cells (Figure 2(c)) showed dead cells (red) as a result 
of exposure with ZDEC-PU and live cells (green) with well-
preserved morphology when exposed to PE. These data 
completely correlated with the cytocompatibility data 
obtained by CTB assay shown in Figure 2(b).
The assays were optimized in murine in vitro dermal 
construct demonstrating that both assays can be adapted to 
this 3D system (Figure 3(a)). This experiment was per-
formed to know if the cell viability can be assessed for the 
same sample at multiple time points. For this, the reagent 
exposure time was 2 h only, at every 2 days, leading to 
washing and feeding with fresh media until the following 
measurement. The results of repeated reagent exposure 
and as an end-point reagent exposure were compared. 
Cells were viable for at least 20 days in matrix, which was 
a prerequisite for in vitro experiments. Furthermore, effect 
of repeated CTB reagent exposure on viability of L929 
cells in 3D matrix demonstrated that this reagent had no 
toxic effect for at least 18 days’ exposure (Figure 3(b)). 
Therefore, this assay can be used as a method to monitor 
cytotoxic effect of the same sample in this 3D system over 
an extended period, at multiple time points.
NHDF cells in 2D and 3D models: 
cytocompatibility evaluation
CTB assay was performed with primary cells of skin, that 
is, NHDF and NHEK (Figure 4(a)). The experiment 
showed an increasing viability signal with an increase in 
cell number showing that CTB assay is suitable on these 
cell types. This concept was further demonstrated by mon-
itoring the cytocompatibility of ISO standardized positive 
(PE) and negative control materials (ZDEC-PU) with 
NHDF (Figure 4(a)). However, microscopic observations 
(Figure 4(c)) showed that CTB reagent affected cell mor-
phology (shrunken cells) of NHDF, suggesting reagent 
interference with cell normal biological activity and pos-
sibly resulting less reliable data.
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In an exploration of an appropriate viability assay for 
NHDF, RTG MT assay was selected because of its contin-
uous-read format to analyze cell viability in real time. The 
assay is based on the ability of viable cells to reduce a 
substrate to produce a luminescent signal by NanoLuc® 
luciferase. This assay did not show linearity of lumines-
cence signal with an increasing time (Figure 5). Similar 
results were obtained with L929 cells (data not shown), 
demonstrating that the linearity in the signal was only pre-
sent when using a lower cell number than 1250, irrespec-
tive of cell type. For this reason, this assay was not suitable 
for 3D systems that involve higher cell number.
Finally, CTG assay was performed: it is based on the 
generation of luminescent signal, proportional to the 
amount of ATP present in cells. The assay showed an 
increasing viability signal with an increase in cell number 
(Figure 6(a)). Half-life of luminescent signal was assessed 
as >4 h (data not shown) and CTG assay was found to be 
an optimal cell viability assay among those analyzed.
Human in vitro dermal construct showed the filopodia-
like morphology with dendritic extensions in the matrix 
and a uniform distribution of NHDF in different planes 
inside the matrix (Figure 6(b)).
After selecting CTG assay as an appropriate assay for 
this cell type, the assay adapted to 3D system by changing 
the shaking time to optimize the cell lysing ability for ATP 
release. Increased shaking time resulted in higher cell lytic 
capacity for the maximum ATP release: 60 min shaking 
time for a cultured dermal construct on day 7 showed 2.4 
times higher luminescent signal for ATP release than shak-
ing for 5 min (Figure 6(c)). This demonstrated that, NHDFs 
were viable inside the matrix. If an increased ATP content 
with time was due to proliferating NHDF inside, the matrix 
needs further exploration using a proliferation assay 
(Figure 6(d)).
Discussion
Type I collagen is a fibrous protein and a major structural 
component of extracellular matrix (ECM) in skin and thus 
can simulate the 3D in vivo cell environment. Collagen 
type I from “rat tail tendons” well serves the purpose of 
ECM because of its irregular fibrils formation that resem-
bles more in vivo-like reconstitution. Interactions between 
fibroblasts and ECM are the core of 3D cell cultures, 
which is different from the focal and fibrillar adhesions on 
Figure 1. Morphology of L929 cells in 2D versus 3D. Bright field (left) and fluorescence micrographs (right) of L929 on 2D flat 
surface (Panel a) and inside 3D col. I matrix (Panel b). Fluorescent staining was performed using Live/Dead staining kit (Calcein-AM 
and EthD-III). Scale bar = 200 µm.
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2D surfaces.34 Cells in 3D have enhanced cell biological 
activities and narrowed integrin usage,34 displaying a dis-
tinctive morphology (as seen in Figures 1 and 6(b)).
Among the cytocompatibility assays, resazurin-based 
assay recognized as the AlamarBlue® or CTB is exceed-
ingly used because it is sensitive as well as cost-effec-
tive.35 This assay works well with an established 2D cell 
culture system; however, to assess the cytotoxic effect of 
therapeutics in the 3D cell culture system, it has to be re-
evaluated to get more reliable results. The test has been 
previously used to screen cytocompatibility of cell sphe-
roids after treatment with an agent, for example, stauro-
sporine, able to distrup the tight cell junctions for resazurin 
uptake.36 In this study, the test was succesfully adapted to 
matrix-based 3D system of “murine in vitro dermal con-
struct,” measuring the cell viability at different time intervals 
(Figure 3).
Resazurin is reported nontoxic to cells for short-term 
incubation times, but can affect cell survivability for 
extended exposure times (in terms of days) by interfering 
with the cell’s metabolic activity, DNA content, and glu-
cose consumption depending on the cell line.37 Changes in 
morphology is a cell’s stress response to an environmental 
insult that can result in fragmentation of Golgi complex, 
swelling of mitochondria, compromised integrity of nucle-
oli, or alterations in cytoskeleton especially in intermediate 
Figure 2. (a) CellTiter-Blue® (CTB) assay with L929 cells. The graph shows cell viability data of L929 cells analyzed using 
CTB assay. (b) Cytotoxicity evaluation of control materials. The cytocompatibility of ISO standardized positive and negative 
control materials with L929 cells monitored using CTB and CTO assays. PE indicates polyethylene and ZDEC-PU indicates zinc 
diethyldithiocarbamate containing polyurethane, while TCPS is tissue culture polystyrene. (c) Live/dead staining. The fluorescent 
micrographs show L929 cells after exposure with the control materials. Staining was performed using Live/Dead staining kit showing 
dead cells as red and live cells as green. Scale bar = 100 µm. Significant difference between viability values of TCPS control and 
ZDEC-PU was p = 0.0001, and between viability values of lysis control and PE it was p = 0.0009.
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filaments.38–40 In this study, an altered morphology of 
NHDF that might be resulting from a collapsed cytoskele-
ton was observed after a short-term exposure (≤1 h when 
the reduction of the blue resazurin to pink resorufin has not 
fully occurred yet) of CTB reagent (Figure 4(c)). Therefore, 
to provide definitive viability data in a clinically relevant 
3D model based on human primary cells (that is more sen-
sitive than a model based on cell lines), a panel of cytocom-
patibility assays was tested for NHDF. In this regard, RTG 
MT assay lost (Figure 5) its linearity at a very low cell seed-
ing density. Here, the substrate concentration can be a lim-
iting factor as well as the cell itself, based on the fact that 
the number of cells (and the subsequent metabolism) does 
not change any more. In this case, an increase in the sub-
strate concentration would not solve that effect. As per 
company’s recommendation, it was strongly needed to test 
the best cell number for each respective cell type for RTG 
MT assay. This nonlinearity effect was further tested with 
L929 cell line. The effect stayed similar (results not shown) 
and, thus, was not suitable for our 3D system.
However, the most advanced and sensitive assay for 
testing viability of 3D systems has been the CTG assay, 
based on the quantification of intracellular ATP content.28 
This assay can be employed on 3D spheroids after opti-
mizing the lysis conditions.29–32,41 For the “human in vitro 
dermal construct” developed in this work, CTG assay was 
selected and experimental parameters for reagent penetra-
tion were optimized. In 3D systems, there are strong cell-
to-cell and cell-to-matrix interactions resulting in tight 
junctions that hinder the reagent uptake. In this study, CTG 
assay was used for “human in vitro dermal construct” 
(matrix-based) for the first time, by optimizing the “shak-
ing time” to enhance reagent penetration for the maximum 
ATP release (Figure 6(c)) and thus cell viability of NHDF 
was measured inside the matrix (Figure 6(d)). However, 
shaking times varied for the measurement of cell viability 
Figure 3. (a) Cell viability of murine in vitro dermal construct (based on L929 cells). The graph shows cell viability (blue bars) and 
cytotoxicity (red bars) assessment of murine 3D dermal construct (based on L929 cells) over time analyzed by CellTiter-Blue® 
(CTB) and CytoTox-ONE™ (CTO) assays. (b) Effect of repeated reagent’s exposure on 3D L929 cells. The viability of constructs 
that were repeatedly exposed to CTB reagent was measured for 18 days.
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of matrix-based 3D system at different time points, indi-
cating the varying matrix–cell interaction with increasing 
culture time. CTG assay was found to be the optimal cell 
viability assay for 3D matrix-based dermal system among 
those studied in this work.
The modified protocol for 3D system used a longer shak-
ing time of 60 min in our 3D system to improve reagent pen-
etration in comparison with 5-min shaking time (as described 
by company for monolayer cell culture). Therefore, it was 
important that half-life showed the stability of the signal 
over time, thus providing the flexibility for measuring time.
The parameters that are important in optimizing an 
assay in a 3D system include type of cells, number of cells, 
period of cultivation, frequency of media exchange, cul-
ture conditions, type of assay, reagent interaction with 
cells, assay conditions, detection range of assay, and signal 
half-life. Depending on the intrinsic characteristics of a 3D 
system, for example, spheroids are different from cells 
embedded in a 3D matrix; extrinsic parameters have to be 
defined differently for each system. For this reason, a port-
folio of assays is crucial to be tested for each cell type in 
2D and then in 3D system.
Figure 4. (a) CellTiter-Blue® (CTB) assay with human primary cells. The graph shows cell viability data of human skin primary 
cells, that is, normal human dermal fibroblasts (NHDF) and normal human epidermal keratinocytes (NHEK) analyzed by 
CTB and CytoTox-ONE™ (CTO) assays. (b) Cytotoxicity evaluation of control materials with human dermal fibroblasts. The 
cytocompatibility of ISO standardized positive and negative control materials with NHDF monitored using CTB and CTO assays. 
PE indicates polyethylene, ZDEC-PU indicates zinc diethyldithiocarbamate containing polyurethane, while TCPS is tissue culture 
polystyrene. Significant difference between viability values of TCPS control and ZDEC-PU was p = 0.0022; and between viability 
values of lysis control and PE it was p = 0.0016. (c) Effect of CTB reagent on cell’s morphology. Bright field micrographs show NHEK 
and NHDF with and without CTB reagent exposure. Scale bar = 100 µm.
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Conclusion
Development of human-based 3D in vitro systems will 
serve as an advanced and more complex system in the 
future, to perform more reliable in vitro preclinical studies 
for the bioevaluation of cytotoxicity of biomedical mate-
rials. Although a 3D model based on human primary cells 
is clinically more relevant, it is more sensitive. In this 
study, the differences in morphology were shown when 
cells were grown on a 2D surface and inside the 3D 
matrix. Moreover, different cell viability assays were 
tested to adapt to the matrix-based 3D systems. The CTB 
assay was adapted by optimizing the test design to the 3D 
system. It worked well with 3D murine in vitro dermal 
constructs (based on L929 cells), but affected the cell 
morphology of NHDF (unlike L929). In an exploration of 
the assays tested with NHDF, CTG was found to be the 
most optimal in this study. This assay was adapted to 3D 
human in vitro dermal constructs by optimizing the “shaking 
Figure 6. (a) CellTiter-Glo® (CTG) assay with human primary cells. The graph shows the cell viability data of human skin primary 
cells, that is, normal human dermal fibroblasts (NHDF) and normal human epidermal keratinocytes (NHEK) analyzed by CTG assay. 
(b) Visualization of 3D NHDF inside human in vitro dermal construct. The fluorescent micrographs from top to bottom show the 
Z-stacked images of in vitro human dermal construct revealing the NHDF inside the matrix. Staining was performed using DAPI and 
Phalloidin. Scale bar = 100 µm. (c) Optimization of CTG assay with human in vitro dermal construct. The graph shows the results 
of viability of NHDF in 3D matrix of dermal construct demonstrating the optimization of shaking time. (d) Cell viability of human in 
vitro dermal construct. The bar graph shows the cell viability of 3D dermal construct analyzed by optimized CTG assay at different 
time points of 7 and 14 days of culture.
Figure 5. RealTime-Glo™ MT (RTG MT) assay with human 
dermal fibroblasts. The graph shows the cell viability data of 
normal human dermal fibroblasts (NHDF) analyzed by RTG MT 
assay at different time points of 0, 8, and 24 h (T0 h T8 h T24 h).
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time” to enhance the reagent penetration and thus, the 
maximum ATP release (assisted by parallel Z-stack micro-
scopic observation for confirmation of cell lysis through-
out the depth of human in vitro dermal construct), 
indicating 2.4 times higher viability value by shaking it 
for 60 min compared to 5 min, a time stated in the standard 
protocol of the respective assay for monolayer cell cul-
tures. There is a need for more than one type of test meth-
ods to reveal all the different aspects of nonphysiological 
or pathophysiological reactions, respectively, occurring in 
this system. Measuring more than one parameter would 
offer more valid data.
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